Brought to you by 
Bayer, Wilmer Eye Institute sign five-year deal
17 Jun 2015
Executive Summary
Through a collaboration with Johns Hopkins University's Wilmer Eye Institute, Bayer HealthCare Pharmaceuticals AG received an option to license exclusive rights to drug candidates they discover and develop for multiple retinal diseases including AMD, diabetic macular edema, geographic atrophy, Stargardt's disease, and retinal vein occlusion.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer, Wilmer Eye Institute sign five-year deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice